Tags

Type your tag names separated by a space and hit enter

The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.
Acta Neurol Scand. 2011 Feb; 123(2):117-21.AN

Abstract

OBJECTIVES

To determine the relationship between apolipoprotein E (APOE) polymorphisms to the time to appearance of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.

METHODS

The APOE genotype of 155 consecutive patients treated with levodopa was determined and its effect on the time of onset of LID was examined using Cox regression model, controlling for gender, age of disease onset, time to initiation of levodopa treatment and history of smoking.

RESULTS

Two patients were homozygous for the APOE ε2 allele, 7 had ε2/ε3, 1 had ε2/ε4, 130 had ε3/ε3, 12 had ε3/ε4 and 3 had ε4/ε4; LID appeared in 57.4% of the patients, appearing 4.1 ± 3.5 years after the initiation of levodopa treatment. The survival curve for LID was not affected by the APOE genotype (P = 0.34).

CONCLUSION

APOE polymorphisms were found not to be associated with either the occurrence or the time to development of LID.

Authors+Show Affiliations

Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Tel-Aviv, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21108621

Citation

Molchadski, I, et al. "The Role of Apolipoprotein E Polymorphisms in Levodopa-induced Dyskinesia." Acta Neurologica Scandinavica, vol. 123, no. 2, 2011, pp. 117-21.
Molchadski I, Korczyn AD, Cohen OS, et al. The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. Acta Neurol Scand. 2011;123(2):117-21.
Molchadski, I., Korczyn, A. D., Cohen, O. S., Katzav, A., Nitzan, Z., Chapman, J., & Hassin-Baer, S. (2011). The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. Acta Neurologica Scandinavica, 123(2), 117-21. https://doi.org/10.1111/j.1600-0404.2010.01352.x
Molchadski I, et al. The Role of Apolipoprotein E Polymorphisms in Levodopa-induced Dyskinesia. Acta Neurol Scand. 2011;123(2):117-21. PubMed PMID: 21108621.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. AU - Molchadski,I, AU - Korczyn,A D, AU - Cohen,O S, AU - Katzav,A, AU - Nitzan,Z, AU - Chapman,J, AU - Hassin-Baer,S, PY - 2010/11/27/entrez PY - 2010/11/27/pubmed PY - 2011/4/27/medline SP - 117 EP - 21 JF - Acta neurologica Scandinavica JO - Acta Neurol Scand VL - 123 IS - 2 N2 - OBJECTIVES: To determine the relationship between apolipoprotein E (APOE) polymorphisms to the time to appearance of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. METHODS: The APOE genotype of 155 consecutive patients treated with levodopa was determined and its effect on the time of onset of LID was examined using Cox regression model, controlling for gender, age of disease onset, time to initiation of levodopa treatment and history of smoking. RESULTS: Two patients were homozygous for the APOE ε2 allele, 7 had ε2/ε3, 1 had ε2/ε4, 130 had ε3/ε3, 12 had ε3/ε4 and 3 had ε4/ε4; LID appeared in 57.4% of the patients, appearing 4.1 ± 3.5 years after the initiation of levodopa treatment. The survival curve for LID was not affected by the APOE genotype (P = 0.34). CONCLUSION: APOE polymorphisms were found not to be associated with either the occurrence or the time to development of LID. SN - 1600-0404 UR - https://www.unboundmedicine.com/medline/citation/21108621/The_role_of_apolipoprotein_E_polymorphisms_in_levodopa_induced_dyskinesia_ L2 - https://doi.org/10.1111/j.1600-0404.2010.01352.x DB - PRIME DP - Unbound Medicine ER -